Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Myriad Genetics Inc MYGN

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.


NDAQ:MYGN - Post by User

Bullboard Posts
Post by AviseAnalyticson Mar 08, 2022 10:36am
95 Views
Post# 34495035

4 STOCKS OPENING NEW FRONTIERS IN WOMEN’S HEALTH!

4 STOCKS OPENING NEW FRONTIERS IN WOMEN’S HEALTH!

$MYGN $SERA $PGNY $MYOV
 
8th March celebrates the cultural, political and socioeconomic achievements of women from different strata and geographies across the globe. Femtech, a category that leverages technology to address issues related to women’s health, is poised to become a $50 billion dollar industry by year 2025, according to estimates by Frost & Sullivan.
 
There are many companies in the clinical diagnostics, biotechnology, biopharmaceutical and medical device space that are dedicated to improving the lives of women, by addressing health issues such as cancers, endometritis and fertility management among others. We take a look at some of them that are at the forefront of innovation in women’s health:
 
Read on to know more:

https://www.aviseanalytics.com/4-stocks-opening-new-frontiers-in-womens-health/

Bullboard Posts